Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal
Fierce Biotech
Thu, 07/9/15 - 07:45 pm
Tags:
AstraZeneca, Japan, Entocort
Will India Issue a Compulsory License for an AstraZeneca Diabetes Pill?
WSJ Pharmalot
Thu, 07/9/15 - 10:28 am
Tags:
India, diabetes, AstraZeneca, Gleevec
AstraZeneca, Ironwood to seek Chinese approval for linaclotide following positive results in late-stage IBS-C trial
First Word Pharma
Wed, 07/8/15 - 09:53 am
Tags:
AstraZeneca, Ironwood, China, linaclotide, IBS-C
AstraZeneca and Teva Settle Allegations of Underpaying Medicaid Rebates
WSJ Pharmalot
Tue, 07/7/15 - 09:42 am
Tags:
AstraZeneca, Teva Pharmaceutical, Medicaid, Medicare
Bad news for AstraZeneca: FDA lays out roadmap for would-be Symbicort copycats
Fierce Pharma
Wed, 07/1/15 - 04:10 pm
Tags:
FDA, AstraZeneca, Symbicort, biosimilars
Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis
Fierce Biotech
Wed, 07/1/15 - 10:41 am
Tags:
AstraZeneca, antibiotics, Entasis, R&D
AstraZeneca loses second top executive as Vectura gets new CEO
Yahoo/Reuters
Wed, 06/24/15 - 08:21 am
Tags:
AstraZeneca, Vectura
Emerging markets still beat elsewhere for Big Pharma growth, with AstraZeneca in the lead
Fierce Pharma
Tue, 06/23/15 - 11:46 am
Tags:
emerging markets, Big Pharma, AstraZeneca, Pfizer, Sanofi
Despite insider sale, Receptos stock surges on takeover rumors
BioPharma Dive
Thu, 06/18/15 - 11:14 am
Tags:
Receptos, M&A, AstraZeneca, Teva Pharmaceutical, Gilead Sciences, MS, multiple sclerosis
AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports
Fierce Pharma
Tue, 06/16/15 - 12:08 pm
Tags:
diabetes, side effects, heart failure, pancreatitis, Nesina, Takeda, Onglyza, AstraZeneca, Farixga, Byetta, Victoza, Januvia, Merck, Novo Nordisk
AstraZeneca R&D executive Morrison to lead cancer firm Syndax
Yahoo/Reuters
Mon, 06/15/15 - 09:28 am
Tags:
AstraZeneca, R&D, cancer, Briggs Morrison, Syndax
AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
Yahoo
Sun, 06/14/15 - 10:50 pm
Tags:
AstraZeneca, lesinurad, febuxostat, tophaceous gout
AZ chief med officer abruptly quits, CEO Soriot to oversee late-stage R&D
BioPharma Dive
Fri, 06/12/15 - 10:53 am
Tags:
AstraZeneca, R&D, Pascal Soriot
Some heartburn drugs linked to increased risk of heart attack
Medical Marketing and Media
Fri, 06/12/15 - 10:47 am
Tags:
heartburn, heart attack, Nexium, Prilosec, Prevacid, AstraZeneca, Takeda, P&G, proton pump inhibitors
AstraZeneca R&D chief Briggs Morrison makes an unexpected exit
Fierce Biotech
Wed, 06/10/15 - 10:59 am
Tags:
AstraZeneca, R&D
SEC: Insider traders lined their pockets on AstraZeneca's $1.3B Ardea deal
Fierce Biotech
Tue, 06/9/15 - 11:45 pm
Tags:
SEC, insider trading, AstraZeneca, Ardea Biosciences, M&A
AstraZeneca takes its emerging markets push to Algeria with $125M expansion
Fierce Pharma
Fri, 06/5/15 - 10:45 am
Tags:
AstraZeneca, emerging markets, Algeria
AZ's Soriot lashes out at U.K.'s refusal to pay for first-in-class cancer drug
Fierce Pharma
Wed, 06/3/15 - 11:35 am
Tags:
AstraZeneca, Pascal Soriot, UK, olaparib
AstraZeneca’s Soriot Open to Buying Immune-Therapy Company
Bloomberg
Tue, 06/2/15 - 04:36 pm
Tags:
AstraZeneca, Pascal Soriot, M&A, CAR-T, Juno Therapeutics
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
Tue, 06/2/15 - 10:06 am
Tags:
biotech, ASCO, Bristol-Myers Squibb, Immunogen, Oncothyreon, Clovis Oncology, CTI BioPharma, Exelixis, Roche, Amgen, AstraZeneca, Puma Biotechnology, Vascular Biogenics, Immunomedics, Momenta, Eli Lilly, Juno Therapeutics, Express Scripts

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.